CL2020002505A1 - Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk - Google Patents

Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk

Info

Publication number
CL2020002505A1
CL2020002505A1 CL2020002505A CL2020002505A CL2020002505A1 CL 2020002505 A1 CL2020002505 A1 CL 2020002505A1 CL 2020002505 A CL2020002505 A CL 2020002505A CL 2020002505 A CL2020002505 A CL 2020002505A CL 2020002505 A1 CL2020002505 A1 CL 2020002505A1
Authority
CL
Chile
Prior art keywords
dabrafenib
trametinib
pharmaceutical combination
erk inhibitor
triple
Prior art date
Application number
CL2020002505A
Other languages
English (en)
Inventor
Matthew John Meyer
Youzhen Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020002505A1 publication Critical patent/CL2020002505A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está relacionada con una combinación farmacéutica que comprende dabrafenib, trametinib y un inhibidor de Erk; composiciones farmacéuticas que la comprenden; y métodos para usar tales combinaciones y composiciones en el tratamiento o la prevención de afecciones en las cuales la inhibición de la vía MAPK es beneficiosa, por ejemplo, en el tratamiento de cánceres.
CL2020002505A 2018-03-30 2020-09-28 Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk CL2020002505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862650744P 2018-03-30 2018-03-30

Publications (1)

Publication Number Publication Date
CL2020002505A1 true CL2020002505A1 (es) 2021-03-05

Family

ID=66397350

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002505A CL2020002505A1 (es) 2018-03-30 2020-09-28 Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk

Country Status (13)

Country Link
US (1) US20210121460A1 (es)
EP (1) EP3773586A1 (es)
JP (1) JP2021519285A (es)
KR (1) KR20200138303A (es)
CN (1) CN111936141A (es)
AU (1) AU2019246719B2 (es)
BR (1) BR112020019577A2 (es)
CA (1) CA3094780A1 (es)
CL (1) CL2020002505A1 (es)
IL (1) IL277380A (es)
MX (1) MX2020010231A (es)
RU (1) RU2020135055A (es)
WO (1) WO2019186488A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516155A (ja) * 2020-02-28 2023-04-18 ノバルティス アーゲー ダブラフェニブ、ｅｒｋ阻害剤及びｒａｆ阻害剤又はｐｄ－１阻害剤を含む三重の医薬品の組合せ
EP4110338A1 (en) * 2020-02-28 2023-01-04 Novartis AG A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2298768E (pt) 2004-06-11 2012-12-05 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
LT3063143T (lt) * 2013-11-01 2018-08-10 Novartis Ag Aminoheteroarilbenzamidai, kaip kinazės inhibitoriai
CA2991805A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
EP3515446B1 (en) * 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor

Also Published As

Publication number Publication date
BR112020019577A2 (pt) 2021-01-05
MX2020010231A (es) 2020-10-28
CN111936141A (zh) 2020-11-13
WO2019186488A1 (en) 2019-10-03
JP2021519285A (ja) 2021-08-10
CA3094780A1 (en) 2019-10-03
US20210121460A1 (en) 2021-04-29
AU2019246719A1 (en) 2020-10-01
AU2019246719B2 (en) 2022-06-16
RU2020135055A (ru) 2022-05-05
EP3773586A1 (en) 2021-02-17
IL277380A (en) 2020-11-30
KR20200138303A (ko) 2020-12-09

Similar Documents

Publication Publication Date Title
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
CL2020002032A1 (es) Cristal de un compuesto derivado de 7,8-difluoro-6,11-dihidrodibenzotiepina, composición farmacéutica, útil en reducir el tiempo de alivio de los síntomas de la influenza para tratar y/o prevenir una infección provocada por el virus de la influenza. (divisional solicitud 201900325).
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX2017006832A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX2019001011A (es) Compuestos farmaceuticos.
MX391217B (es) Moduladores de rodopsina p23h con especificidad de alelo.
CL2019002557A1 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.
MX2022013081A (es) Compuestos para el tratamiento de sars.
CL2018000688A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias
MX2017011000A (es) Compuestos de pirazol sustituidos como inhibidores de serina proteasa.
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
MX2017009246A (es) Farmaco de combinacion.
MX2017011018A (es) Inhibicion de la actividad de olig2.
CL2021000018A1 (es) Oligonucleótidos para modular la expresión de rtel1
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF